Lapatinib and gemcitabine for metastatic pancreatic cancer: A phase II study

被引：0
|
作者：
Safran, H.
Miner, T.
Bahary, N.
Whiting, S.
Lopez, C.
Sun, W.
Charpentier, K.
Charpentier, K.
Shipley, J.
Anderson, E.
McNulty, B.
机构：
[1] Brown Univ, Oncol Grp, Providence, RI 02912 USA
[2] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[3] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[4] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[5] Univ Penn, Ctr Canc, Philadelphia, PA 19104 USA
[6] Brown Univ, Rhode Isl Hosp, Providence, RI 02903 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15653
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Ko, Andrew H.
    Venook, Alan P.
    Bergsland, Emily K.
    Kelley, R. Kate
    Korn, W. Michael
    Dito, Elizabeth
    Schillinger, Brian
    Scott, Janet
    Hwang, Jimmy
    Tempero, Margaret A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (06) : 1051 - 1057
  • [22] Phase II study of gemcitabine in patients with metastatic breast cancer
    Blackstein, M
    Vogel, CL
    Ambinder, R
    Cowan, J
    Pearce, P
    Iglesias, J
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 664 - 664
  • [23] A phase II study of tipifarnib and gemcitabine in metastatic breast cancer
    Clinton Yam
    Rashmi K. Murthy
    Vicente Valero
    Janio Szklaruk
    Girish S. Shroff
    Carol J. Stalzer
    Aman U. Buzdar
    James L. Murray
    Wei Yang
    Gabriel N. Hortobagyi
    Stacy L. Moulder
    Banu Arun
    Investigational New Drugs, 2018, 36 : 299 - 306
  • [24] A phase II study of tipifarnib and gemcitabine in metastatic breast cancer
    Yam, Clinton
    Murthy, Rashmi K.
    Valero, Vicente
    Szklaruk, Janio
    Shroff, Girish S.
    Stalzer, Carol J.
    Buzdar, Aman U.
    Murray, James L.
    Yang, Wei
    Hortobagyi, Gabriel N.
    Moulder, Stacy L.
    Arun, Banu
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (02) : 299 - 306
  • [25] Phase II study of gemcitabine in patients with advanced pancreatic cancer
    Carmichael, J
    Fink, U
    Russell, RCG
    Spittle, MF
    Harris, AL
    Spiessi, G
    Blatter, J
    BRITISH JOURNAL OF CANCER, 1996, 73 (01) : 101 - 105
  • [26] A phase II study of gemcitabine and flutamide in advanced pancreatic cancer
    Mayer, A
    Shaw, J
    'Ath, SD
    Price, P
    Blesing, C
    Corrie, P
    BRITISH JOURNAL OF CANCER, 2000, 83 : 18 - 18
  • [27] A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer
    Tomao, S
    Romiti, A
    Massidda, B
    Ionta, MI
    Farris, A
    Zullo, A
    Brescia, A
    Santuari, L
    Frati, L
    ANTICANCER RESEARCH, 2002, 22 (04) : 2361 - 2364
  • [28] Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study
    E Van Cutsem
    C-P Li
    E Nowara
    G Aprile
    M Moore
    I Federowicz
    J-L Van Laethem
    C Hsu
    C K Tham
    S M Stemmer
    R Lipp
    A Zeaiter
    A Fittipaldo
    Z Csutor
    B Klughammer
    X Meng
    T Ciuleanu
    British Journal of Cancer, 2014, 111 : 2067 - 2075
  • [29] Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study
    Van Cutsem, E.
    Li, C-P
    Nowara, E.
    Aprile, G.
    Moore, M.
    Federowicz, I.
    Van Laethem, J-L
    Hsu, C.
    Tham, C. K.
    Stemmer, S. M.
    Lipp, R.
    Zeaiter, A.
    Fittipaldo, A.
    Csutor, Z.
    Klughammer, B.
    Meng, X.
    Ciuleanu, T.
    BRITISH JOURNAL OF CANCER, 2014, 111 (11) : 2067 - 2075
  • [30] Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study
    Alberts, SR
    Townley, PM
    Goldberg, RM
    Cha, SS
    Sargent, DJ
    Moore, DF
    Krook, JE
    Pitot, HC
    Fitch, TR
    Wiesenfeld, M
    Mailliard, JA
    ANNALS OF ONCOLOGY, 2003, 14 (04) : 580 - 585
12345